Researchers Develop New Surgical Procedure For Treating Epiphora
- byDoctor News Daily Team
- 03 August, 2025
- 0 Comments
- 0 Mins

A team of otolaryngologists and ophthalmologists at Toho University Sakura Medical Center has developed a new procedure, 'conjunctivoductivo-dacryocystorhinostomy' for treating Epiphora.
Under normal conditions, tears in the eyes are drained into the lacrimal sac through small openings called the upper and lower puncta located at the inner corner of the eye (called medial canthus). The tears go through small ducts called the superior and inferior canaliculi and then flow through the lacrimal sac and the nasolacrimal duct, and finally into the nose (Figure 1a). Obstruction in any part of the above-mentioned passage is the most common cause of watery eyes or epiphora. Epiphora affects the quality of life (QOL) of patients. When both the upper and lower canaliculi are obstructed, the tear fluid cannot be drained into the nose, resulting in epiphora. Although the cause of canalicular obstruction cannot be identified in many cases, it is thought to be associated with aging, trauma, tumors, and oral anticancer medication.
A minor surgery to enlarge the canaliculus by inserting a silicone tube is the common treatment to remove the obstructions. When the canaliculus is reoccluded or cannot be kept open, A Jones tube placement is considered, which semi-permanently places a glass tube that directly connects the nasal cavity and medical canthus. Otherwise, a surgery with an external incision may be considered, which leaves a scar of approximately 2 cm on the side of the nose.
To overcome the disadvantages of these conventional surgical methods, a new procedure, 'conjunctivoductivo-dacryocystorhinostomy.' has been developed.
All surgical procedures are performed under general anesthesia. First, the entire lacrimal duct and lacrimal sac are exposed and elevated, and then the lacrimal duct is cut at the lower end (Fig 1b). At the medial canthus, the conjunctiva is incised (Fig 1b). The end of the cut lacrimal duct is withdrawn from the conjunctival incision and sutured to form a new lacrimal punctum (Fig 1c). Then the medial wall of the lacrimal sac is opened wide (Fig 1c). Now, the former lacrimal duct and lacrimal sac become the new lacrimal passage, and the tear fluid flows in this newly made passage.
The newly developed procedure, 'conjunctivoductivo-dacryocystorhinostomy' for the intractable canalicular obstruction does not leave any facial scarring or place foreign matter in the body. We believe that this procedure can help improve the QOL of patients with epiphora," said Dr. Munetaka Ushio, lead author of the study. The study was published in The Laryngoscope on October 1, 2021
https://onlinelibrary.wiley.com/doi/10.1002/lary.29861
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:
Recent News
Chennai: Fortis Healthcare Opens 250-Bedded 2nd Mu...
- 06 July, 2025
New Lab-On-A-Chip, Cheaper, Faster, On The Spot Di...
- 06 July, 2025
Steroids And Plasma Exchange Do Not Alter Prognosi...
- 14 February, 2020
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!